In autoimmune hepatitis (AIH), GLS antagonists like JHU083 and DON not only attenuate T cell activation and reduce the Th1/Th17 ratio but also downregulate SLC7A5 mRNA expression, further dampening mTOR pathway activation [95, 96]. Here, SLC7A5 is linked to autoimmune hepatitis.